SCHEDULE: BlackRock Reports 4.7% Stake in Solid Biosciences
Ownership Filing
BlackRock, Inc. has disclosed a beneficial ownership of 4.7% in Solid Biosciences Inc. as of March 31, 2026, holding 4,578,650 shares.
Summary
- BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Solid Biosciences Inc. common stock.
- As of March 31, 2026, BlackRock beneficially owns 4,578,650 shares, representing 4.7% of the class of securities.
- The filing indicates that BlackRock has sole voting power over 4,515,473 shares and sole dispositive power over 4,578,650 shares.
- No single person's interest in Solid Biosciences Inc. common stock exceeds five percent, according to the filing.
- The filing is made in accordance with Rule 13d-1(b) and reflects securities owned by certain reporting business units of BlackRock, Inc.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of institutional ownership and does not provide new operational or financial performance information about Solid Biosciences Inc.
Positives
- BlackRock, a significant institutional investor, has a substantial stake in Solid Biosciences, which can be viewed as a positive signal of confidence.
- The company's shares are held in the ordinary course of business, not for the purpose of changing or influencing control.
Risks
- The filing does not contain specific forward-looking statements or risk factors related to Solid Biosciences Inc.'s business operations.
Future Outlook
The filing does not contain specific forward-looking statements or guidance from Solid Biosciences Inc. It primarily reports BlackRock's current ownership stake.
Industry Context
StockSavvy.ai notes that the filing of a Schedule 13G by a major asset manager like BlackRock typically indicates a passive investment stake, often held on behalf of various funds and clients. This filing does not suggest an activist or controlling interest in Solid Biosciences Inc.
Stakeholder Impact
- Shareholders: The filing confirms a significant institutional investor's passive stake, which may influence market perception but does not directly alter company operations or governance.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Previous Power of Attorney dated. |
| 01/21/2025 | Effective date of the current Power of Attorney granted by BlackRock, Inc. |
| 03/31/2026 | Date of event requiring filing of this statement (ownership reporting). |
| 04/27/2026 | Date of signature for the Schedule 13G filing. |
Keywords
Solid Biosciences, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Ownership Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.